^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

Study to Evaluate the Safety and Anti-tumor Activity of SCC244

Excerpt:
...In Phase Ia, histologically confirmed NSCLC (including sarcomatoid carcinoma) with c-Met alterations defined as c-Met gene amplification ≥ 5 copies or c-Met protein overexpression (IHC 3+) or c-Met exon 14 skipping mutation....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

A phase I clinical trial to assess the safety, pharmacokinetics, and antitumor activity of glumetinib (SCC244) in patients with advanced non-small cell lung cancers (NSCLCs).

Published date:
05/28/2020
Excerpt:
Glumetinib was well tolerated at doses up to 400 mg once daily and demonstrated clinical activity in advanced NSCLC with MET alterations….4 patients (3 with MET amplification) had a best of response of stable disease.
DOI:
10.1200/JCO.2020.38.15_suppl.e21702
Trial ID: